Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXEDRINE vs CABERGOLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, infertility),Prolactin-secreting pituitary adenomas (microadenomas and macroadenomas)
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
Primarily metabolized by CYP2D6 to 4-hydroxydextroamphetamine, which is further metabolized to various metabolites. Also undergoes deamination and oxidation.
Extensively metabolized in the liver, primarily by hydrolysis and minor CYP3A4 involvement.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
Approximately 16-20% bound; primarily to albumin
40-42% bound to plasma proteins, primarily albumin.
3.5-4.5 L/kg; indicates extensive tissue distribution, particularly CNS
Approximately 100-150 L/kg, indicating extensive tissue distribution; Vd is large (≥100 L/kg) due to high lipophilicity and tissue binding.
Oral: 75-100% (immediate-release), 70-90% (extended-release); rectal and parenteral routes are not clinically utilized
Oral bioavailability is about 40-45% (range 30-60%) due to first-pass metabolism. No parenteral formulations are commonly used.
GFR 15–30 m L/min: use with caution, consider dose reduction by 50%. GFR <15 m L/min: not recommended.
No dosage adjustment recommended for mild to moderate renal impairment (Cr Cl >10 m L/min); avoid use in severe renal impairment (Cr Cl <10 m L/min) due to lack of data.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh class C) as elimination may be reduced.
Age 3–5 years: 2.5 mg orally once daily, increase by 2.5 mg weekly as needed (max 40 mg/day). Age ≥6 years: 5 mg orally once or twice daily, increase by 5 mg weekly (max 40 mg/day).
Not FDA approved for pediatric use; limited data: 0.025-0.05 mg/kg once weekly, titrated cautiously based on prolactin levels; maximum 0.1 mg/kg weekly.
Start at lowest dose (2.5–5 mg orally once daily), titrate slowly; monitor for cardiovascular effects, agitation, and weight loss.
No specific adjustment recommended; start at lower end of dosing range (0.25 mg twice weekly) due to potential for increased sensitivity and age-related decline in renal function.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including DEXEDRINE, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Cabergoline is associated with an increased risk of cardiac valve regurgitation, especially at high doses used for Parkinson's disease. The risk appears lower at doses used for hyperprolactinemia, but caution is advised.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, manic episodes, and aggression,Seizures in patients with prior seizure history,Long-term suppression of growth in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when co-administered with serotonergic drugs
Cardiac valvulopathy: monitor with echocardiography before and during therapy,Pleural, pericardial, and retroperitoneal fibrosis,Postural hypotension,Impulse control disorders (e.g., pathological gambling, hypersexuality),Remission of prolactinomas may reduce pituitary function
Known hypersensitivity to amphetamine products or other components of DEXEDRINE,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis),Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse
Hypersensitivity to cabergoline or ergot derivatives,Uncontrolled hypertension,History of cardiac valvular disease,Pregnancy: use only if clearly needed (category B)
Avoid high-fat meals with immediate-release formulations as they may delay absorption; for extended-release, high-fat meals can increase peak concentration. Acidic foods (e.g., citrus fruits, fruit juices, carbonated drinks) can reduce absorption. Avoid excessive caffeine (coffee, tea, energy drinks) as it may exacerbate central nervous system stimulation and cardiovascular effects. Maintain adequate hydration. Grapefruit and other CYP2D6 inhibitors may increase effects.
Avoid high-fat meals that may increase absorption variability. No specific food restrictions, but take consistently with meals to maintain stable levels. Grapefruit juice may theoretically increase cabergoline exposure (CYP3A4 inhibition); avoid excessive consumption.
First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (hyperactivity, irritability, feeding difficulties). Dextroamphetamine is a sympathomimetic amine with potential for vasoconstriction reducing uteroplacental perfusion.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasoconstriction may cause fetal hypoxia; use only if benefit outweighs risk. Second and third trimesters: risk of postpartum hemorrhage and uterine atony if used for lactation suppression; avoid in pregnancy due to potential for fetal harm from dopamine agonist effects.
Dextroamphetamine is excreted into breast milk; M/P ratio not established but concentration about 2-7 times maternal plasma. potential for infant stimulation, insomnia, and growth impairment. American Academy of Pediatrics recommends use during breastfeeding only if benefits outweigh risks; monitor infant for agitation and poor weight gain.
Cabergoline suppresses lactation; contraindicated in breastfeeding women because it reduces milk production. If used, discontinue breastfeeding or avoid drug. M/P ratio not established; drug is excreted in rat milk, unknown in humans.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and enhanced renal clearance may reduce serum concentrations of dextroamphetamine. Dose adjustment may be necessary based on clinical response; start with lowest effective dose and monitor for worsening ADHD symptoms. Avoid in severe hypertension or preeclampsia.
No standard dose adjustment recommended; avoid use during pregnancy unless absolutely necessary (e.g., prolactinoma). Pregnancy may alter cabergoline pharmacokinetics (increased volume of distribution, decreased clearance) but specific dose modifications are not established. If used, monitor prolactin levels and clinical response.
Monitor for hypertension, tachycardia, and mental status changes (psychosis, mania) especially at high doses. Avoid late-day dosing to prevent insomnia. Use with caution in patients with pre-existing cardiovascular disease or hyperthyroidism. Dextroamphetamine can suppress appetite and cause weight loss; monitor growth in children. Abuse potential is high; schedule II controlled substance. Can precipitate tics in susceptible individuals. Contraindicated within 14 days of MAOIs due to hypertensive crisis.
Start with 0.25 mg twice weekly, titrate by 0.25 mg every 2-4 weeks based on prolactin levels and tolerability. Maximum dose typically 1 mg twice weekly. May cause orthostatic hypotension; caution when rising from supine position. Use lowest effective dose to minimize risk of valvulopathy, especially with cumulative doses >2 mg/day. Discontinue if signs of cardiac fibrosis. Monitor for impulse control disorders (e.g., hypersexuality, gambling). Avoid in patients with uncontrolled hypertension or pre-existing cardiac valvular disease.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew the extended-release capsules; swallow whole.,Avoid taking the medication in the evening or close to bedtime to prevent trouble sleeping.,Report any chest pain, shortness of breath, fainting, or rapid heart rate to your doctor immediately.,Contact your doctor if you experience new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania.,You may experience decreased appetite and weight loss; maintain a healthy diet and inform your doctor if weight loss is significant.,Do not stop taking abruptly; taper dose under medical supervision to avoid withdrawal symptoms.,This medication has potential for abuse and dependence; keep in a safe place and do not share with others.,Avoid alcohol and caffeine as they may increase side effects like jitteriness and heart palpitations.,Tell all healthcare providers you are taking this medication, especially before surgery or dental procedures.
Take with food to reduce gastrointestinal upset.,Avoid alcohol as it may increase side effects like dizziness or nausea.,Rise slowly from sitting or lying positions to prevent fainting.,Report any new shortness of breath, swelling, or chest pain immediately.,Notify your doctor if you experience unusual urges (gambling, sex, spending).,Do not drive or operate machinery if you feel dizzy or drowsy.,Take exactly as prescribed; do not double the dose if missed.,Store at room temperature away from moisture and heat.
No interactions on record
"Trazodone, a serotonin antagonist and reuptake inhibitor, and cabergoline, a dopamine D2 receptor agonist, exhibit opposing effects on the dopaminergic and serotonergic systems, potentially leading to reduced therapeutic efficacy and increased risk of adverse effects such as serotonin syndrome or dopaminergic toxicity. The combination may precipitate hypertensive crises or cardiac valvulopathy due to additive effects on 5-HT2B receptor activation by cabergoline, while trazodone's blockade of serotonin reuptake can exacerbate serotonin excess. Clinical outcomes include unpredictable blood pressure fluctuations, neuropsychiatric disturbances, and rare but serious cardiovascular events."
"Cabergoline, a dopamine D2 receptor agonist used for hyperprolactinemia, may inhibit the metabolism of methylene blue, a monoamine oxidase inhibitor (MAOI) used for methemoglobinemia. This interaction can lead to elevated methylene blue levels, increasing the risk of serotonin syndrome, characterized by hyperthermia, agitation, and neuromuscular abnormalities. Clinically, patients may present with confusion, tachycardia, and hypertension, necessitating cautious use."
"Cabergoline, a dopaminergic ergot derivative, acts as a vasoconstrictor via agonism of serotonin 5-HT2B and dopamine D1 receptors in vascular smooth muscle. Nadolol, a non-selective beta-blocker, inhibits beta-2 adrenergic receptor-mediated vasodilation, leaving alpha-adrenergic vasoconstriction unopposed. The combined vasoconstrictive effects can lead to additive peripheral and coronary vasoconstriction, potentially causing severe hypertension, myocardial ischemia, or Raynaud's phenomenon."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXEDRINE vs CABERGOLINE, answered by our medical review team.
DEXEDRINE is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.. CABERGOLINE is a Dopamine Agonist that works by Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXEDRINE and CABERGOLINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXEDRINE is: 5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.. The standard adult dose of CABERGOLINE is: 0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXEDRINE and CABERGOLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXEDRINE is classified as Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of pr. CABERGOLINE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasocon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.